Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

百时美施贵宝 (BMY.US)宣布，欧盟委员会 (EC)已批准其重磅PD-1抑制剂Opdivo (nivolumab)与CTLA-4靶向抗体Yervoy (ipilimumab)联用，一线治疗不可切除或晚期肝细胞癌 (HCC)成人患者。据悉，美国FDA已接受Opdivo联合Yervoy治疗同一患者群体的补充生物制品许可申请，预计在今年4月21日之前完成审评。

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer. The FDA has accepted a ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a decision expected by June 2025. The FDA accepted the supplemental biologics ...

Phase 2 data have shown promising efficacy with nivolumab combined with ipilimumab in this patient population, and data already published from the ongoing, phase 3 CheckMate 8HW trial show ...

The triplet regimen of cabozantinib, nivolumab, and ipilimumab improved PFS in aRCC patients but did not enhance OS compared to the doublet regimen. Patients receiving the triplet regimen experienced ...